ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Amgen to acquire 20.5% stake in BeiGene for $2.7 billion

by Ryan Cross
November 9, 2019 | APPEARED IN VOLUME 97, ISSUE 44

 

Amgen has struck a deal to buy 20.5% of BeiGene, a Chinese cancer drug company, for $2.7 billion—a 36% premium over BeiGene’s stock price when the deal was announced. BeiGene will commercialize three Amgen drugs in China, and the companies will share profits. The two will also work together to develop 20 new drug candidates from Amgen’s pipeline. BeiGene will commit up to $1.25 billion to the project.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment